Interferon treatment of chronic hepatitis C patients with normal or near normal or near normal alanine-amino-transferase levels: Might it be harmful rather than useful?

International Hepatology Communications

Volumn 6, Issue 1, 1996, Pages 8-15

  Ideo G ^a   Bellobuono, A ^a   Tempini, S ^a   Bellati, G ^a   Romano L ^b   Zanetti, A R ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

interferon; alanine amino transferase; chronic hepatitis C; HCV genotype; HCV RNA titre

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0030297816     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4346(96)00320-9     Document Type: Article

References (14)

1. [1] Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 443-449.
2. [2] Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-698.
3. [3] Salmeron J, Pérez Ruiz M, Palacios A, et al. Interferon (IFN) α treatment of chronic hepatitis C (CHC) with normal vs elevated alanine aminotransferase. J Hepatol 1995; 23(Suppl. 1): 105.
4. [4] Serfaty L, Chazouilleres O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996; 110: 291-295.
5. [5] Van Thiel DH, Caraceni P, Molloy PJ. et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon α2b therapy. J Hepatol 1995; 23: 503-508.
6. [6] Sangiovanni A, Spinzi GC, Ceriani R, et al. Randomized controlled trial of HCV healthy carriers treatment with Interferon (IFN). Hepatology 1995; 22(suppl. to N.4): 290 A.
7. [7] Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type specific primers: application to clinical surveys and tracing infections sources. J Gen Virol 1992; 73: 673-679.
8. [8] Manzin A, Bagnarelli P, Menzo S, et al. Quantitation of hepatitis C virus genome molecules in plasma samples. J Clin Microbiol 1994; 32: 1939-1944.
9. [9] Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara L. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464-465.
10. [10] Naito M, Hayashi N, Hagiwara H, et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994; 19(4): 871-875.
11. [11] Davis GL, Lindsay K. Albrecht J. et al. Predictors of response to recombinant alpha-interferon treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J Viral Hepatitis 1994; 1: 55-63.
12. [12] Yoshioka K, Higashi Y, Yamada M, et al. Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver 1995; 15: 57-62.
13. [13] Pagliaro L, Craxi' A, Cammana' C, et al. Interferon alfa for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-828,.
14. [14] Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-a2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 1237-1280.